Bone Metastases - Featured Article

Article

Bone Complications: An Unavoidable Side-Effect of Cancer Treatment in the Elderly?

 

Osteoprosis and osteopenia and are increasingly common in cancer patients, due both to the aging population and new forms of cancer treatment. This week we feature

Lodovico Balducci's article

on bone complications of cancer treatment in the elderly. One of ONCOLOGY's own Editors in Chief, Bill Wood from the UNC Lineberger Comprehensive Cancer Center

comments

, and Drs Cohen and Naeim from the David Geffen School of Medicine also share their

viewpoint 

on this topic of increasing importance.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Tim Cortese
December 6th 2025
Article

Elevated LDH levels were associated with worse PFS and OS outcomes in patients with relapsed/refractory multiple myeloma treated with elranatamab.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Fixed-duration venetoclax regimens with obinutuzumab or ibrutinib showed noninferior PFS vs continuous single-agent ibrutinib in the phase 3 CLL17 trial.

Fixed-Duration Venetoclax Combos Show Noninferior PFS to Ibrutinib in CLL

Gina Mauro
December 6th 2025
Article

Fixed-duration venetoclax regimens with obinutuzumab or ibrutinib showed noninferior PFS vs continuous single-agent ibrutinib in the phase 3 CLL17 trial.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

The 2-year EFS end point was met in the cohort of patients given non-TBI conditioning and allogeneic HCT among those with B-ALL who are pre-HCT and NGS MRD-negative.

Efficacy Outcomes Remain Consistent Without Total Body Irradiation in B-ALL

Ariana Pelosci
December 6th 2025
Article

The 2-year EFS end point was met in the cohort of patients given non-TBI conditioning and allogeneic HCT among those with B-ALL who are pre-HCT and NGS MRD-negative.

Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.

How Has Teclistamab Administration Translated Into Community MM Settings?

ONCOLOGY Staff
December 6th 2025
Article

Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.